Search Results

• • 12 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.

  Authors:Minggui Wang, Michelle Earley, Liang Chen, Blake M Hanson, Yunsong Yu, Zhengyin Liu, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 20221,393 words Clinical report

   Abstract Only

• Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial.

  Authors:Constance Delaugerre, Frantz Foissac, Hendy Abdoul, Guillaume Masson, Laure Choupeaux, Eric Dufour, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022632 words Report

   Abstract Only

• Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.

  Authors:Mahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, Irfan Zaidi, Zonghui Hu, Bourama Kamate, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022890 words Report

   Abstract Only

• Facial Balamuthia mandrillaris infection with neurological involvement in an immunocompetent child.

  Authors:Zhen Zhang, Jianying Liang, Ruoqu Wei, Xiaobo Feng, Lei Wang, Liuhui Wang, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022312 words Brief article

   Abstract Only

• The importance of understanding the infectious microenvironment.

  Authors:Thomas Bjarnsholt, Marvin Whiteley, Kendra P Rumbaugh, Philip S Stewart, Peter Ø Jensen, and Niels Frimodt-MøllerFrom:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022313 words Brief article

   Abstract Only

• Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.

  Authors:Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti, Jigeeshu V Divatia, Ravi Jain, Camilla Rodrigues, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022968 words Article

   Abstract Only

• Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.

  Authors:Stephen E Goldstone, Anna R Giuliano, Joel M Palefsky, Eduardo Lazcano-Ponce, Mary E Penny, Robinson E Cabello, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 20221,037 words Article

   Abstract Only

• Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer--BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.

  Authors:Eric J Haas, John M McLaughlin, Farid Khan, Frederick J Angulo, Emilia Anis, Marc Lipsitch, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022548 words Article

   Abstract Only

• Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.

  Authors:Devashish Desai, Adil Rashid Khan, Manish Soneja, Ankit Mittal, Shivdas Naik, Parul Kodan, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022590 words Report

   Abstract Only

• Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.

  Authors:Jeanne Rini Poespoprodjo, Faustina Helena Burdam, Freis Candrawati, Benedikt Ley, Niamh Meagher, Enny Kenangalem, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022742 words Report

   Abstract Only

• The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.

  Authors:Charlotta Edlund, Anders Ternhag, Gunilla Skoog Ståhlgren, Petra Edquist, Åse Östholm Balkhed, Simon Athlin, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 2022767 words Article

   Abstract Only

• Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

  Authors:Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Reynaldo Chandler, et al.From:The Lancet Infectious Diseases (Vol. 22, Issue 3) Peer-Reviewed

  Mar. 20221,743 words Article

   Abstract Only